{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-303234","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.764658+00:00","generated_at":"2026-06-21T05:31:51.196089+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Frequency Therapeutics expects FX-322-208 trial results in H2 Q1 2023","bullets":["Posted updated corporate slide presentation on Dec 13, 2022.","FX-322-208 Phase 2 trial results expected second half of Q1 2023.","FX-322 is an investigational regenerative therapy for sensorineural hearing loss."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-303234","json":"https://secwatch.observer/filing/0001193125-22-303234.json","markdown":"https://secwatch.observer/filing/0001193125-22-303234.md","text":"https://secwatch.observer/filing/0001193125-22-303234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312522303234/0001193125-22-303234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312522303234/d425973d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:31:51.196089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}